227 related articles for article (PubMed ID: 38562891)
21. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
[TBL] [Abstract][Full Text] [Related]
22. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
23. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
Mayer F; Gunawan AL; Tso P; Aponte GW
Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
[TBL] [Abstract][Full Text] [Related]
25. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
26. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.
Seino Y; Yabe D
J Diabetes Investig; 2013 Mar; 4(2):108-30. PubMed ID: 24843641
[TBL] [Abstract][Full Text] [Related]
27. The expanding incretin universe: from basic biology to clinical translation.
Drucker DJ; Holst JJ
Diabetologia; 2023 Oct; 66(10):1765-1779. PubMed ID: 36976349
[TBL] [Abstract][Full Text] [Related]
28. Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
Stensen S; Krogh LL; Sparre-Ulrich AH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Gasbjerg LS; Knop FK
Diabetes Obes Metab; 2022 Sep; 24(9):1882-1887. PubMed ID: 35491518
[No Abstract] [Full Text] [Related]
29. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo.
Dong Y; Carty J; Goldstein N; He Z; Hwang E; Chau D; Wallace B; Kabahizi A; Lieu L; Peng Y; Gao Y; Hu L; Betley JN; Williams KW
Mol Metab; 2021 Dec; 54():101352. PubMed ID: 34626854
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
31. Hypothalamic control of interoceptive hunger.
Siemian JN; Arenivar MA; Sarsfield S; Aponte Y
Curr Biol; 2021 Sep; 31(17):3797-3809.e5. PubMed ID: 34273280
[TBL] [Abstract][Full Text] [Related]
32. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
33. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
34. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
35. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
[TBL] [Abstract][Full Text] [Related]
36. The incretin/glucagon system as a target for pharmacotherapy of obesity.
Del Prato S; Gallwitz B; Holst JJ; Meier JJ
Obes Rev; 2022 Feb; 23(2):e13372. PubMed ID: 34713962
[TBL] [Abstract][Full Text] [Related]
37. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
[TBL] [Abstract][Full Text] [Related]
38. Variation in responses to incretin therapy: Modifiable and non-modifiable factors.
Austin GO; Tomas A
Front Mol Biosci; 2023; 10():1170181. PubMed ID: 37091864
[TBL] [Abstract][Full Text] [Related]
39. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
[TBL] [Abstract][Full Text] [Related]
40. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation.
Alsalim W; Lindgren O; Ahrén B
J Diabetes Investig; 2023 Mar; 14(3):354-361. PubMed ID: 36539382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
